Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Azelon Pharmaceuticals
Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.
Private Company Edition: In other $100m-plus venture capital rounds, Third Harmonic Bio emerged with $155m, including a new $105m series B round. Also, Europe- and Japan-focused Newton Biocapital launched its second VC fund with €50m in initial capital and a €150m fundraising goal.
US FDA inspections lead to warning letters for Aurobindo and Health Plus, while Emergent BioSolutions site escapes nearly unscathed; Sun waits for Halol revisit and Jubilant suffers poor-quality costs as agency investigators resume domestic surveillance post-omicron.
After filing for Chapter 11 bankruptcy protection in October last year, Teligent has sewn up the sales of its Buena manufacturing site and ANDAs, with an auction process providing mixed results.
- Drug Delivery
- Other Names / Subsidiaries
- Zelos Therapeutics Inc.